thumbnail
Deal MakingJ&J expands immunotherapy portfolio with $850m Proteologix buyJ&J expands immunotherapy portfolio with $850m Proteologix buy
Johnson & Johnson (J&J) will acquire bispecific antibody developer Proteologix for $850 million in cash and additional milestone payments.